Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
GLP-1s and Employer Coverage In 2024, more employers paid for GLP-1-based obesity treatments compared to 2023
Avoid using at the same time as: Strong exfoliating acids
GLP-1 receptor agonists are currently licensed for the treatment of type 2 diabetes and for weight management in overweight/obese individuals
But heres the good news: we now have tools that can help
GLP-1 receptor agonists would not replace these evidence-based interventions, though they might be used concurrently to manage associated metabolic complications such as diabetes, if clinically appropriate and under specialist guidance
Product type
US$ 28.10
US$ 27.37
US$ 26.70
US$ 22.75
US$ 23.17
US$ 23.02
US$ 24.07
US$ 24.76
